In its most recent quarter, Mercury Systems reported revenue growth of 10.2% year on year, beating analysts’ expectations by 9.5% and delivering year-over-year increases in backlog, adjusted EBITDA, ...
Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback